There is no generic version of Vraylar (cariprazine) available. The FDA has not approved any generic alternatives, which means the brand-name product from AbbVie remains the only option. For a medication that can cost over $1,500 for a 30-day supply without insurance, that’s a significant issue for many people paying out of pocket.
Why Vraylar Has No Generic Yet
Vraylar is protected by patents that prevent other manufacturers from producing a generic copy. Until those patents expire or are successfully challenged, no competing version can enter the market. There is no confirmed date for when a generic will become available.
This is fairly common for newer psychiatric medications. Vraylar was first approved by the FDA in 2015, and brand-name drugs typically hold exclusivity for years after launch. Other atypical antipsychotics like aripiprazole (Abilify) and quetiapine (Seroquel) eventually got generics, but only after their patent protections ran out, which took well over a decade in each case.
What Vraylar Is Used For
Vraylar is FDA-approved to treat schizophrenia in adults and to manage acute manic or mixed episodes in bipolar I disorder. It has also been studied for bipolar depression, where clinical trials showed meaningful improvements in depression scores compared to placebo. The medication works differently from most other antipsychotics: it has a strong preference for a specific type of dopamine receptor (D3), with roughly 6 to 10 times higher affinity for D3 receptors than D2 receptors. This receptor profile is unique among available antipsychotics and may explain why it affects motivation and mood symptoms in ways that other medications in the class do not.
Vraylar comes in capsule form at four strengths: 1.5 mg, 3 mg, 4.5 mg, and 6 mg. For schizophrenia, doses range from 1.5 to 6 mg once daily. For bipolar mania, the typical range is 3 to 6 mg daily. Treatment usually starts at the lowest dose and increases over several days based on how you respond.
What It Costs Without a Generic
Without insurance, Vraylar is expensive. A 30-day supply of the 4.5 mg or 6 mg capsules starts around $1,566. The 1.5 mg and 3 mg capsules are packaged in 20-count supplies starting around $1,046. These prices make it one of the more costly medications in its class, and the absence of a generic means there’s no cheaper bioequivalent alternative at the pharmacy counter.
If you have commercial insurance that doesn’t cover Vraylar, the manufacturer offers a savings card that can bring your cost down to as little as $75 for a 30-day supply. You need to be 18 or older, a U.S. or Puerto Rico resident, and enrolled in the program. A maximum savings limit applies, so the exact amount you pay can vary depending on your insurance plan.
Patient Assistance for Uninsured or Underinsured
AbbVie runs a patient assistance program called myAbbVie Assist for people with limited or no insurance coverage. Eligibility is based on household income: a single person earning $63,840 or less per year qualifies, as does a household of two earning $86,560 or less, three at $109,280, or four at $132,000. Each additional family member adds $22,720 to the threshold. If you have a commercial plan that requires you to use the assistance program as a condition of coverage, you’re not eligible.
Your prescriber’s office can help initiate the application through AbbVie’s patient access support line. The process involves verifying your income and insurance status, and approval can take some time, so it’s worth starting early if you anticipate needing help covering the cost.
Common Side Effects to Know About
The most notable side effect of Vraylar is akathisia, a restless, can’t-sit-still feeling that affected about 7.6% of patients in bipolar depression trials, compared to 2.1% on placebo. At the lower 1.5 mg dose, the rate was 5.5%; at 3 mg, it climbed to 9.6%. Other movement-related side effects occurred in about 4.5% of patients on Vraylar versus 2.1% on placebo. These rates are worth knowing because akathisia can be distressing enough that some people stop taking the medication, and recognizing it early makes it easier to address with your prescriber.
Other Options While Waiting for a Generic
If cost is the primary barrier, several other atypical antipsychotics are available in generic form and treat overlapping conditions. Aripiprazole, for instance, shares some pharmacological similarities with Vraylar as a partial dopamine agonist, though it lacks the strong D3 receptor preference. Quetiapine, risperidone, and olanzapine are all available as generics and used for schizophrenia and bipolar disorder, though each has a different side effect profile.
Switching medications is a conversation to have with your prescriber, since Vraylar’s unique receptor activity means it may work for people who haven’t responded well to other options. But if you’re paying full price out of pocket and struggling with the cost, a therapeutic alternative that’s available as a generic could save you over a thousand dollars a month.